Trial of THEO-260 in Ovarian Cancer Patients

A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.

Trial Details

NCT ID
NCT06618235
Phase
PHASE1 / PHASE2
Sponsor
Theolytics Limited
Status
RECRUITING
Cancer Type
High-Grade Serous Ovarian Cancer
Interventions
  • THEO-260
Locations (sample)
  • Madrid, Spain|40.4165,-3.70256
  • Glasgow, Scotland, United Kingdom|55.86515,-4.25763
  • London, United Kingdom|51.50853,-0.12574
  • Oxford, United Kingdom|51.75222,-1.25596

Key Eligibility Criteria

  • Confirmed histological diagnosis of advanced high grade serous or endometrioid cancer of the fallopian tube, primary peritoneum or ovary either on …
  • Platinum-resistant disease (radiological recurrence/ progression with 6 months of prior platinum treatment), primary platinum-refractory disease (r…
  • Life expectancy of \> 3 months.
  • ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find High-Grade Serous Ovarian Cancer Trials on Trialify →